RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report

被引：4
|
作者：
Zhang, Tongyi [1 ]
Wang, Hongwei [2 ]
Cai, Zhiwei [2 ]
Zhang, Siqi [3 ]
Jiang, Chongyi [1 ,2 ]
机构：
[1] Fudan Univ, Huadong Hosp, Dept Gen Surg, Shanghai, Peoples R China
[2] Fudan Univ, Huadong Hosp, Dept Hepatobiliary Pancreat Surg, Shanghai, Peoples R China
[3] 3D Med Inc, Med Dept, Shanghai, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词：
pancreatic cancer; RET fusion; pralsetinib; target therapy; RET inhibitors; SOLID TUMORS; PHASE; 1/2; FUSION; EFFICACY; LUNG;
D O I：
10.3389/fonc.2023.1078076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously reported. Herein, we presented a case of a 68-year-old man with pancreatic cancer harboring TRIM33-RET fusion who responded remarkably to pralsetinib despite being intolerant to chemotherapy. To our knowledge, this is the first report on the clinical value of a single TRIM33-RET fusion in pancreatic cancer, which may benefit from the targeted therapy.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
    Ou, Kai
    Liu, Xiu
    Li, Weihua
    Yang, Yi
    Ying, Jianming
    Yang, Lin
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [2] Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
    Nannini, Margherita
    Repaci, Andrea
    Ricco, Gianluca
    Ianni, Manuela
    Golemi, Arber
    Maiolo, Vincenzo
    Ferrari, Marco
    Natali, Filippo
    Rizzini, Elisa Lodi
    Monari, Fabio
    Solaroli, Erica
    De Leo, Antonio
    Maloberti, Thais
    Pantaleo, Maria A.
    De Biase, Dario
    Tallini, Giovanni
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report
    Wu, Ying
    Yan, Zhecheng
    Pan, Juan
    Chang, Xiaona
    Huang, Bo
    Luo, Danju
    Meng, Rui
    Shi, Heshui
    Fan, Jun
    Nie, Xiu
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [4] Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report
    de Jong, Loek A. W.
    Sparidans, Rolf W.
    van den Heuvel, Michel M.
    [J]. CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 1579 - 1585
  • [5] Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report
    Ying Wu
    Zhecheng Yan
    Juan Pan
    Xiaona Chang
    Bo Huang
    Danju Luo
    Rui Meng
    Heshui Shi
    Jun Fan
    Xiu Nie
    [J]. World Journal of Surgical Oncology, 20
  • [6] Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer
    Kassir, Nastya
    Mcdougall, David
    Kuruvilla, Denison
    Kim, Sean
    Kumar, Shaun
    Rahman, Ahmadur
    Ruf, Thorsten
    Cheeti, Sravanthi
    Ankrom, Wendy
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (06): : 685 - 696
  • [7] Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report
    Cao, Xiangming
    Liu, Xiongwei
    Wang, Simin
    Liu, Zhen
    Ren, Xin
    Sun, Debin
    Deng, Lichun
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (06)
  • [8] AlectinibTransformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib : case report
    [J]. Reactions Weekly, 2016, 1607 (1) : 35 - 35
  • [9] Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer
    Park, K.
    Tomlins, S. A.
    Mudaliar, K. M.
    Chiu, Y-L
    Esgueva, R.
    Mehra, R.
    Suleman, K.
    Varambally, S.
    Brenner, J. C.
    MacDonald, T.
    Srivastava, A.
    Tewari, A. K.
    Sathyanarayana, U.
    Nagy, D.
    Pestano, G.
    Kunju, L. P.
    Demichelis, F.
    Chinnaiyan, A. M.
    Rubin, M. A.
    [J]. LABORATORY INVESTIGATION, 2011, 91 : 215A - 216A
  • [10] Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer
    Park, K.
    Tomlins, S. A.
    Mudaliar, K. M.
    Chiu, Y-L
    Esgueva, R.
    Mehra, R.
    Suleman, K.
    Varambally, S.
    Brenner, J. C.
    MacDonald, T.
    Srivastava, A.
    Tewari, A. K.
    Sathyanarayana, U.
    Nagy, D.
    Pestano, G.
    Kunju, L. P.
    Demichelis, F.
    Chinnaiyan, A. M.
    Rubin, M. A.
    [J]. MODERN PATHOLOGY, 2011, 24 : 215A - 216A
12345